ARTV (Artiva Biotherapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ARTV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Fred Aslan | Chief Executive Officer | Sell | — | — |
| 2026-09-08 | Elaine K. Sorg | Director | A | — | — |
| 2026-09-08 | Daniel G. Baker | Director | A | — | — |
| 2026-09-08 | Laura Stoppel | Director | A | — | — |
| 2026-09-08 | ELIZABETH L HOUGEN | Director | A | — | — |
| 2026-09-08 | ALISON MOORE | Director | A | — | — |
| 2026-09-08 | BRIAN DANIELS | Director | A | — | — |
| 2026-09-08 | Rajeev M. Shah | Director | A | — | — |
| 2026-09-04 | Jennifer Bush | COO, CLO, Compliance Officer | Sell | — | — |
| 2026-09-04 | Christopher Horan | Chief Tech Operations Officer | Sell | — | — |
| 2026-09-04 | Subhashis Banerjee | Chief Medical Officer | Sell | — | — |
| 2026-09-04 | Fred Aslan | Chief Executive Officer | Sell | — | — |
| 2026-08-31 | Subhashis Banerjee | Chief Medical Officer | MIXED | — | — |
| 2026-08-19 | Subhashis Banerjee | Chief Medical Officer | MIXED | — | — |
| 2026-07-31 | RA Capital Nexus Fund, L.P. | Director | Buy | — | — |
| 2026-07-28 | RA Capital Nexus Fund, L.P. | Director | Buy | — | — |
| 2026-07-23 | RA Capital Healthcare Fund LP | Director | Buy | — | — |
| 2026-07-23 | RA Capital Nexus Fund, L.P. | Director | Buy | — | — |
| 2026-07-20 | Peter Kolchinsky | Director | Buy | — | — |
| 2026-07-14 | Rajeev M. Shah | Director | Buy | — | — |
| 2026-06-29 | Rajeev M. Shah | Director | Buy | — | — |
| 2026-06-16 | RA Capital Nexus Fund, L.P. | Director | Buy | — | — |
| 2026-06-11 | RA Capital Nexus Fund, L.P. | Director | Buy | — | — |
| 2026-05-28 | GC Cell Corp | 10%+ Owner | Buy | — | — |
| 2026-05-19 | Jennifer Bush | COO, CLO, Compliance Officer | Sell | — | — |
| 2026-05-19 | Christopher Horan | Chief Tech Operations Officer | Sell | — | — |
| 2026-05-19 | Heather Raymon | SVP, Research and Development | Sell | — | — |
| 2026-05-19 | Subhashis Banerjee | Chief Medical Officer | Sell | — | — |
| 2026-05-19 | Gines Diego Miralles | President & Head of R&D | A | — | — |
| 2026-05-19 | Fred Aslan | Chief Executive Officer | Sell | — | — |
| 2026-05-13 | Peter Kolchinsky | Director | Buy | — | — |
| 2026-03-10 | Thad Allen Huston | Chief Financial Officer | A | — | — |
| 2026-02-19 | Elaine K. Sorg | Director | A | — | — |
| 2026-02-18 | Christopher Horan | Chief Tech Operations Officer | MIXED | — | — |
| 2026-02-18 | Heather Raymon | SVP, Research and Development | MIXED | — | — |
| 2026-02-18 | Subhashis Banerjee | Chief Medical Officer | A | — | — |
| 2026-02-18 | Jennifer Bush | COO, CLO, Secy, Compliance Off | MIXED | — | — |
| 2026-02-18 | Fred Aslan | President and CEO | MIXED | — | — |
| 2025-12-15 | Fred Aslan | President and CEO | Sell | — | — |
| 2025-12-12 | Heather Raymon | SVP, Research and Development | A | — | — |
| 2025-12-12 | Jennifer Bush | COO, CLO, Secy, Compliance Off | A | — | — |
| 2025-12-12 | Christopher Horan | Chief Tech Operations Officer | A | — | — |
| 2025-12-12 | Fred Aslan | President and CEO | A | — | — |
| 2025-11-17 | Jennifer Bush | COO, CLO, Secy, Compliance Off | F | — | — |
| 2025-11-17 | Heather Raymon | SVP, Research and Development | F | — | — |
| 2025-11-17 | Christopher Horan | Chief Tech Operations Officer | F | — | — |
| 2025-11-17 | Neha Krishnamohan | Chief Financial Officer | F | — | — |
| 2025-11-17 | Fred Aslan | President and CEO | MIXED | — | — |
| 2025-10-17 | Fred Aslan | President and CEO | Sell | — | — |
| 2025-08-18 | Fred Aslan | President and CEO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 17,304,626 | — |
| — | Director | 16,817,543 | — |
| — | 10%+ Owner | 5,999,703 | — |
| — | 10%+ Owner | 2,606,629 | — |
| — | Chief Executive Officer | 1,449,765 | — |
| — | Director | 1,260,512 | — |
| — | 10%+ Owner | 1,182,054 | — |
| — | 10%+ Owner | 1,058,284 | — |
| — | COO, CLO, Compliance Officer | 329,529 | — |
| — | Chief Tech Operations Officer | 283,084 | — |
| — | Director | 264,571 | — |
| — | Chief Financial Officer | 220,000 | — |
| — | 10%+ Owner | 194,108 | — |
| — | SVP, Research and Development | 148,228 | — |
| — | Chief Medical Officer | 140,947 | — |
| — | Chief Financial Officer | 99,356 | — |
| — | Chief Medical Officer | 80,000 | — |
| — | President & Head of R&D | 77,500 | — |
| — | Director | 68,320 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARTV quote page; the site-wide leaderboard is on the insider transactions hub.